Dufaston (degidrosteron) in treatment of dysfunctional womb bleeding associated with ferrum hyperplasia of endometrium | Zendy

Elena Ulrikh | Zendy; Г. Ф. Кутушева | Zendy; А. Ф. Урманчеева | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Dufaston (degidrosteron) in treatment of dysfunctional womb bleeding associated with ferrum hyperplasia of endometrium

Author(s) -

Elena Ulrikh,

Г. Ф. Кутушева,

А. Ф. Урманчеева

Publication year - 2003

Publication title -

journal of obstetrics and women s diseases

Language(s) - English

Resource type - Journals

eISSN - 1684-0461

pISSN - 1683-9366

DOI - 10.17816/jowd88982

Subject(s) - medicine , dysfunctional uterine bleeding , endometrium , hyperplasia , endometrial hyperplasia , dysfunctional family , somatic cell , gynecology , physiology , endocrinology , clinical psychology , biochemistry , chemistry , gene

Endometrial hyperplasia, being a fairly common gynecological pathology among women of different age groups, requires timely diagnosis and adequate treatment. Duphaston at a dosage of 10-20 mg from 5 to 25 or from 16 to 25 days of the menstrual cycle showed itself as an effective drug (in 83.3%), with sufficient progestogenic antiproliferative activity, with minimal side effects and a neutral effect on the metabolism of lipids and carbohydrates , which made it possible to use it among patients with various somatic pathologies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research